Clinical trials provide evidence of significant benefit with 1st/2nd-generation EGFR-TKIs in early-line treatment of EGFRm-positive NSCLC (8–11, 17, 18), additionally, these agents are recommended in numerous clinical practice guidelines and are included in the WHO Essential Medicines List (19). This evidence concerns the gene EGFR and non-small cell lung carcinoma.